ArticleBlood advances2020

Carden MA, Gaddh M, Hoskote A, et al. Rituximab leads to early elimination of circulating CD20+ T and B lymphocytes in patients with iTTP despite ongoing TPEx. Blood Adv. 2020;4(3):477-481.

PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.